Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 12/20 | 0.83 |
| ▸ | CA9 | Q16790 | 12/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.67 |
| ▸ | HTR7 | P34969 | 2/20 | 0.67 |
| ▸ | HTR6 | P50406 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13150262 | 0.90 | CA12 (0.69) | CA12CA9MEN1KMT2AKDM4E | |
| SCHEMBL13150277 | 0.86 | CA12 (0.67) | CA12CA9MEN1KMT2AKDM4E | |
| SCHEMBL13150267 | 0.85 | CA12 (0.64) | CA12CA9MEN1KMT2AKDM4E | |
| SCHEMBL6768925 | 0.83 | CA12 (0.61) | CA12CA9MEN1KMT2AKDM4E | |
| SCHEMBL13150280 | 0.80 | CA12 (0.57) | CA12CA9MEN1KMT2AKDM4E | |
| SCHEMBL30689513 | 0.79 | CA12 (0.69) | CA12CA9KDM4EALDH1A1POLB | |
| SCHEMBL15836637 | 0.78 | KMT2A (1.00) | CA12CA9MEN1KMT2AKDM4E | |
| Trifluoroacetic Acid SCHEMBL30689498 | 0.78 | KDM4E (0.62) | CA12CA9KDM4EALDH1A1POLB | |
| SCHEMBL15836636 | 0.78 | KMT2A (0.72) | CA12CA9MEN1KMT2AKDM4E | |
| SCHEMBL6229629 | 0.76 | DYRK1A (0.78) | CA12CA9KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2600863-B1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | ESTEVE LABOR DR (ES) | 2018-03-28 | — | — | EP | disclosed |
| EP-2646025-B1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | ESTEVE LABOR DR (ES) | 2017-03-15 | — | — | EP | disclosed |
| EP-2531191-B1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | ESTEVE LABOR DR (ES) | 2016-03-30 | — | — | EP | disclosed |
| EP-2571501-B1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| EP-2460519-A1 | Use of sigma ligands in bone cancer pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2415471-A1 | Use of sigma ligands in opioid-induced hyperalgesia | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-02-08 | — | — | EP | disclosed |
| EP-2388005-A1 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-11-23 | — | — | EP | disclosed |
| EP-2353598-A1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-08-10 | — | — | EP | disclosed |